Amore Pacific (090430): Gangbangcheon B × Geochajesi 9/20 HOLD — Brand Reputation #1 · FY2025A OPM 7.9% V-Recovery · COSRX 140 Countries · De-China Complete (US Overtook China) · 25 Analysts Unanimous BUY (Avg Target +61%) — Enter ₩107,000 After ₩106,000 Support Confirmed · Stop ₩100,000 · T1 ₩130,000 · T2 ₩145,000
South Korea cosmetics brand reputation #1 (Sulwhasoo, Laneige, COSRX, Aestura, illiyoon multi-brand portfolio) · FY2025A operating income ₩336B (OPM 7.9% / +5%p vs. 2023 trough 2.9%) · Q1 2026 OPM 11.2% accelerating · COSRX RX line +24% reconfirmed · Aestura launched in 17 European countries · China share 54% (2019) → 12.8% (2024) · US revenue overtook China in 2025 · 25 analysts unanimous BUY · avg target ₩173,370 (+61%) · K-PER base +22%, optimistic +58%. However: full bearish MA alignment (120d > 60d > 20d > price), conservative K-PER -14%, Geochajesi 9/20 (Vol 2, Chart 2, Catalyst 3, Market 2) → HOLD. Entry: ₩106,000–108,000 support re-confirmed + bullish candle + volume → ₩107,000, stop ₩100,000 (-6.5%), T1 ₩130,000 (R:R 3.3:1), T2 ₩145,000 (R:R 5.4:1). Next earnings: 2026-08-18.
Core Position
South Korea cosmetics brand reputation #1 · FY2025A OPM 7.9% V-shaped recovery · COSRX global dermo 140+ countries · de-China pivot complete (US overtook China) · 25 analysts unanimous BUY (avg. target ₩173,370, +61%) — Gangbangcheon B × Geochajesi 9/20 HOLD. Enter ₩107,000 after ₩106,000 support re-confirmed + bullish candle, stop ₩100,000, targets ₩130,000 (+21%) · ₩145,000 (+35%)
Investment Thesis
Amore Pacific (090430) is rated 'Watch-and-Wait (HOLD)' at Gangbangcheon B × Geochajesi 9/20. Three core strengths: First, earnings recovery clearly visible — FY2025A operating income ₩336B (OPM 7.9%), Q1 2026 OPM 11.2% confirms entry into Cross-Model Quadrant 1 (revenue↑ + margin↑). Second, de-China structural pivot complete — China revenue share collapsed from 54% in 2019 to 12.8% in 2024, with US revenue overtaking China in 2025. COSRX RX line +24% reconfirms the growth engine. Third, extreme undervaluation zone — near 52-week low (₩106,000), 25 analysts unanimous BUY, average target +61% upside. K-PER base and optimistic scenarios both positive. However, entry conditions are not yet met. Chart is in full bearish alignment (120d MA ~₩135,000 > 60d MA ~₩127,000 > 20d MA ~₩122,000 > price), MACD below zero, RSI ~34 near oversold. Conservative K-PER is -14%. Institutional flow remains net-sell through H2 2025 – H1 2026. Three conditions to flip to BUY: ① Geochajesi 14+ recovery (volume surge + institutional net-buy turn), ② 5-day MA golden cross above 20-day MA (bullish alignment start), ③ Q2 2026 earnings (Aug 18) confirming COSRX +20% growth. Until these conditions are met, register as a watchlist name and await the ₩106,000–108,000 support zone. Do not enter without all conditions confirmed.
① Non-Financial — K-Beauty Multi-Brand Platform + De-China Global Rebalancing
Amore Pacific's core moat is the combination of brand equity and R&D DNA. The multi-tier portfolio — Sulwhasoo (luxury oriental 30yr), Laneige (US Gen-Z penetration, lip treatment #1), COSRX (140-country dermo platform), Aestura (Oliveyoung dermo #1), and illiyoon (body care #1) — structurally prevents single-brand dependency. Korea's first cosmetics research lab (established 1954, 70-year R&D heritage, 470+ researchers, 6 global R&D sites) is the source of brand trust. Governance is founder-centric (Chairman Suh Kyung-bae holds 50.13% direct/indirect), aligning interests — but succession uncertainty (both daughters have limited management experience) is a medium-term risk. Business model in one sentence: recurring skincare consumable purchases + multi-brand ecosystem (Beauty Point membership) + channel/geographic diversification sustains revenue. → Full 5-layer analysis in the Non-Financial tab.
② Validator — Gangbangcheon B × Geochajesi 9/20 = Transition-Stage Company, HOLD
Gangbangcheon 5 steps: Step 1 (Industry) ✅ — global skincare TAM 5–6% annual growth, K-content structural tailwind, defensive consumer staple. Step 2 (Market Position) ⚠️ B grade — domestic #1 but global niche-strength stage, indie brands eroding mid-market, pricing power partial. Step 3 (Business Model) ✅ — one-sentence explainable, recurring consumable repurchase, triple scalability (geographic, vertical, platform). Step 4 (Financial Quality) ⚠️ — V-shape recovery in progress (OPM 2.9%→7.9%), ROE 4.5% below threshold, FCF margin estimated 6–8% (ordinary). Step 5 (K-PER) ⚠️ — conservative scenario -14% (fails threshold), base +22%, optimistic +58%. FY2027 OPM 12% achievement is the inflection point. Grade: B (re-evaluable to A if 2027 OPM 12% + COSRX growth sustained). Geochajesi 9/20 — Vol 2, Chart 2, Catalyst 3, Market 2. → Full K-PER 3 scenarios and Geochajesi breakdown in Validator tab.
③ Technical — Full Bearish Alignment + 52-Week Low Inflection, Split-Entry After ₩107,000 Support Confirmed
-33.8% decline from 52-week high ₩169,000 (H1 2025). Full bearish MA alignment (120d ~₩135,000 > 60d ~₩127,000 > 20d ~₩122,000 > price). MACD below zero, RSI ~34 (near oversold, bullish divergence candidate). Fibonacci basis: 2020 low (₩100,000) → 2025 high (₩169,000) — current price is in the 78.6%–100% retracement zone. Falling Wedge pattern candidate — upside breakout expected on completion. Double-bottom (W-bottom) forming with 52-week low ₩106,000 re-test. Preferred scenario: ₩106,000–108,000 support re-confirmed + daily bullish close + above-average volume → enter ₩107,000. Stop ₩100,000 (-6.5%). Targets: T1 ₩130,000 (+21.5%, R:R 3.3:1), T2 ₩145,000 (+35.5%, R:R 5.4:1). Trend-reversal entry: enter ₩131,000 after ₩130,000 breakout on volume, stop ₩126,000, targets ₩145,000 (R:R 2.2:1) · ₩169,000 (R:R 6.2:1). → Full chart and scenario details in Technical tab.
Key Metrics
Price (Analysis Date)
111,800원
2026-06-11 기준 / 52주 고점比 -33.8%
FY2025A Operating Income
336십억원
OPM 7.9% / 전년比 +52% / 2026Q1 OPM 11.2%
K-PER Base Upside
+22%
낙관 +58% / 보수 -14% — 2027 OPM 12% 분기점
Geochajesi
9 / 20
강방천 B · 거2·차2·재3·시2 — 관망
52-Week Range
106,000~169,000원
현재가 111,800원 — 피보 78.6% 되돌림 구간
Next Earnings
2026-08-18
FY2026 Q2 — 코스알엑스 성장 지속 여부 핵심
Bull Case
- Earnings V-shaped recovery + Cross-Model Quadrant 1 confirmed: From OPM trough 2.9% (2023) up to 7.9% (FY2025A) and 11.2% (Q1 2026). Revenue +9.5% (FY2025A), operating income +52%. Company guidance (2027 OPM 12%) is on track. Analyst consensus FY2026E operating income ₩464.6B (+38% YoY). Cross-Model Quadrant 1 (revenue↑ + margin↑) — ideal growth structure confirmed.
- De-China structural pivot complete + COSRX global platform: China share collapsed from 54% (2019) to 12.8% (2024). US revenue overtook China in 2025 (US 32%, China 28% of overseas). COSRX RX line +24% reconfirmed. Aestura launched across 17 European countries. COSRX 140-country distribution network is the new overseas growth platform. Laneige maintains US lip treatment category #1.
- Multi-brand portfolio + MBS channel dominance: Price-tier coverage from Sulwhasoo (luxury) → Laneige (premium) → COSRX (global dermo) → Aestura (dermo-cosmetic) → illiyoon (daily). Dominates key domestic MBS (Oliveyoung) slots: body care (illiyoon #1), shampoo (LaboH #1), dermo (Aestura #1). Structurally diversified against single-brand risk.
- Extreme undervaluation gap: 25 analysts unanimous BUY, average target ₩173,370 (+61% upside vs current). Highest target ₩220,000. This gap near 52-week lows is at a historically extreme level. K-PER base and optimistic scenarios positive. COSRX alone — acquired for ~₩1.5T — represents a significant portion of the current ₩7.4T market cap.
- AI beauty tech + Skin Longevity trend first-mover: CES 2025 Innovation Award (AI skin diagnosis). AI-First strategy (AI applied across R&D, marketing, and sales). Slow-aging and bio-material research direction aligned with global anti-aging market growth. Traditional cosmetics firm in structural transition to beauty-tech platform.
Bear Case
- Full bearish MA alignment + institutional net-sell: -33.8% from 52-week high (₩169,000). 120d/60d/20d MAs all above current price — complete bearish stack. MACD below zero. Institutional flow net-sell through H2 2025 – H1 2026. Foreign investor flows relatively underweighting Amore vs. peers (APR, Cosmax). Bearish technical structure continues until trend reversal confirmed.
- Conservative K-PER upside negative (-14%): Basis FY2025A OI ₩336B, conservative scenario (14%/yr growth × 15x) → target cap ₩6.4T vs. current ₩7.4T = -14%. If 2027 OPM 12% is not achieved or COSRX growth slows, current price cannot be justified. Conservative K-PER failing Step 5 is a fundamental valuation risk.
- COSRX single-dependency risk: 2024–2026 earnings and price action concentrated in one variable — COSRX trajectory. The 2025 temporary growth pause already demonstrated how quickly the stock reacts. Structural growth deceleration vs. one-time Sephora order timing difference cannot be confirmed until Q2 2026 earnings. Consumer price resistance experienced during a price hike attempt. Diversification away from COSRX is still in early stages.
- Succession uncertainty + owner risk: Eldest daughter Suh Min-jung (on extended leave since July 2023); youngest Suh Ho-jung (joined Osulloc as a new hire in 2025). Both daughters lack meaningful management experience. Leadership gap risk after Chairman Suh Kyung-bae. May 2025 pledge of 1.67M shares as collateral — potential signal of governance concern. Large-org decision-speed disadvantage is structural.
- Indie brand structural threat + duty-free channel decline: APR (Medicube), Roundlab, and agile indie brands continue capturing domestic and overseas market share. Fast ODM/OEM product launches exploit the large-corp speed disadvantage. Duty-free channel (historically high-margin) in structural decline — Chinese tourist recovery uncertain. Replacement MBS/online channel margins are lower than duty-free.
Technical Summary
~10 months of decline (-33.8%) since 52-week high (₩169,000, H1 2025). Full bearish MA alignment (120d ~₩135,000 > 60d ~₩127,000 > 20d ~₩122,000 > current ₩111,800). MACD below zero (dead-cross entrenched). RSI ~34 (near oversold, similar to the Oct 2025 low at ~32). Located in Fibonacci 78.6% (₩115,700)–100% (₩100,000) retracement zone. Falling Wedge + 52-week low (₩106,000) double-bottom candidate. Preferred first entry: ₩107,000 after ₩106,000–108,000 support confirmed.
Amore Pacific Technical Analysis — Price, Moving Averages, Support/Resistance, Fibonacci, RSI, MACD
Support
S1: 106,000~108,000원 (52주 저점 구간 — 1차 매수 대기. 이 레벨 이탈 시 추가 하락 가속), S2: 100,000원 (심리적 지지 + 2020년 저점 구간 — 추세 붕괴 확인선·손절 기준)
Resistance
R1: 122,000원 (20일선 추정 — 단기 저항), R2: 127,000원 (60일선 추정 — 중기 저항), R3: 130,000~132,000원 (4월 Q1 발표 후 반등 고점 — 1차 목표 진입 구간), R4: 135,000원 (120일선 추정 — 장기 저항), R5: 145,000~148,000원 (60일선 수렴 예상·2차 목표), R6: 169,000원 (52주 고점 — 신고가 돌파 시 장기 추세 전환)
Trend Analysis
Short-term (20d MA ~₩122,000): Bearish — price ₩111,800 below MA-20. Medium-term (60d MA ~₩127,000): Bearish — price below MA-60. Long-term (120d MA ~₩135,000): Bearish — price below MA-120. MA alignment: fully bearish stack (120d > 60d > 20d > price). Dead-cross: confirmed (bearish alignment entrenched since H2 2025). Trend strength: strongly bearish. Next earnings: 2026-08-18.
Momentum & Indicators
RSI (14) ~34 — near oversold. Oct 2025 low had RSI ~32 and rallied. Current re-entry at similar levels → bullish divergence candidate (if new price low is met with RSI higher than prior trough). MACD: negative (~-2,200 est.), below signal line, histogram negative. If histogram magnitude narrows → fading downside momentum signal. Bollinger Bands: near lower band, contracting (squeeze) — energy accumulation before directional break. Volume: June 11 213,039 shares (vs. avg 138,991, +53%) — watch whether support tests come on elevated volume.
Key Technical Points
The 52-week low zone formed in H2 2025 and currently being re-tested — this is the key first support level. A Hammer or Pin Bar candle with above-average volume at this zone signals a short-term bottom. June 11 2026 intraday low ₩106,900 followed by ₩111,800 close suggests the zone is holding. If this zone breaks (close below ₩100,000) → accelerated downside risk — cancel entry principle.
RSI ~32 at Oct–Nov 2025 lows was followed by a rally. Current re-entry at similar estimated level (~34). Bullish divergence condition: if price makes a new low near ₩106,000 while RSI trough is higher than the prior ~32 low → downside momentum fading signal. However, entering solely on divergence without price confirmation is dangerous. Must pair with a bullish daily close + volume confirmation.
2026 April Q1 post-earnings rally high was ₩131,000 — this level is the immediate resistance. Expected 20-day MA convergence zone and near Fibonacci 50% (₩134,500). A breakout above this level on strong volume, especially if coinciding with a 5d MA golden cross above 20d MA, signals trend reversal. From first-entry (₩107,000), R:R to this first target = 3.3:1. This breakout also triggers scenario 3 (trend-follow entry).
A Falling Wedge structure is forming — lower highs, lower lows, but narrowing range as the lows are declining more slowly. Bollinger Band contraction (squeeze) is in progress; if resolved upward, strong rebound catalyst. Completion condition: upper resistance line (connecting descending highs) broken upward on volume. Pattern not yet confirmed — do not use as a standalone buy signal before breakout confirmation.
Trading Scenarios
Entry
₩107,000 (₩106,000–108,000 support re-confirmed + bullish daily close + above-avg volume)
Stop
₩100,000 (psychological support break, -6.5%)
Target
T1 ₩130,000 (+21.5%, Resistance 1) / T2 ₩145,000 (+35.5%, Resistance 2)
Await pullback to support zone from current price. Higher confidence when Hammer candle + volume confirmed. Allocate 50% of total position, take 50% at T1, pursue T2 with remainder.
Entry
₩111,800 (1/3) + ₩107,000 support touch (1/3) + ₩130,000 breakout confirmed (1/3) → avg ₩116,267
Stop
₩100,000 (-14% vs avg entry)
Target
T1 ₩130,000 (+11.8%) / T2 ₩145,000 (+24.7%)
T1 R:R insufficient. Only recommended if committed to holding to T2 (₩145,000). Third tranche at ₩130,000 breakout acts as trend-follow safety net.
Entry
₩131,000–133,000 (₩130,000 breakout on strong volume + 5d MA golden cross above 20d MA confirmed)
Stop
₩126,000 (Fibonacci 61.8% break, -3.8–5%)
Target
T1 ₩145,000 (+9–10%) / T2 ₩169,000 (52-week high, +27–29%)
Enter after trend reversal confirmed — late entry but easiest risk management. Do not enter without volume + golden cross dual confirmation.
Bullish Signals
₩106,000 re-test + Hammer candle + volume 150%+ of average → Scenario ① entry conditions met
RSI at current low is higher than prior trough (~32) → bullish divergence confirmed, Scenario ① credibility rises
₩130,000 breakout on volume + 5d MA golden cross above 20d MA → trend reversal formalized, Scenario ③ triggered
Q2 2026 earnings (Aug 18) COSRX revenue growth +20%+ confirmed → Geochajesi Catalyst 3→4, buy signal strengthened
Institutional net-buy confirmed (KRX investor flow data) → Geochajesi Vol 2→3, Geochajesi score rises 9→11+
Bearish Risks
₩100,000 daily close break → immediate stop-loss / cancel entry principle. High probability of accelerated downside
Current RSI trough is lower than prior trough (~32) → bullish divergence invalidated, technical bounce credibility falls
Q2 2026 COSRX quarterly revenue negative growth confirmed → target price recalculation required, remove from watchlist
Korea-China (Hallyu Ban) resurgence or escalated geopolitical risk → Sulwhasoo/Innisfree overseas sales hit, further losses possible
MACD histogram negative magnitude re-expanding → downside momentum re-accelerating signal, support break probability rising
* Technical analysis is based on historical data and does not guarantee future returns. Final investment decisions are your own responsibility.
Amore Pacific Growth Dashboard — Revenue/OI Trend, Regional Rebalancing, COSRX Growth, Channel Mix, Business Model
Switching Cost & Moat
Moat Strength by Type
Brand
Sulwhasoo (30yr luxury oriental, global recognition), Laneige (US Gen-Z, lip treatment #1 US), COSRX (dermo 140 countries). Domestic cosmetics brand reputation #1. However, Innisfree brand equity erosion ongoing.
Technology / R&D
Korea's first cosmetics research lab (est. 1954, 70-year R&D DNA). 470+ researchers, 6 global sites. CES 2025 Innovation Award (AI skin diagnosis). Cosmetics patent protection strength is limited.
Channel Network
Key channel relationships: Sephora + Amazon (Americas), Boots (Europe), Oliveyoung (domestic). New entrant channel competition intensifying. COSRX 140-country distribution is the crown-jewel channel asset.
Switching Costs
Skincare's skin-adaptation property creates some brand inertia after acclimatization. Beauty Point membership cross-brand lock-in attempt ongoing. However, abundant substitutes across the K-beauty space limit this moat.
Cost Structure
Economies of scale exist but structural cost advantage vs. indie brands is weak. Global marketing spend surging. Offline channel restructuring costs ongoing. ₩40B voluntary separation package (2025).
Network Effects
B2C consumables — no meaningful network effects. Beauty Point membership cross-brand point sharing attempts a weak platform effect but is minimal in practice.
Amore Pacific's strongest moat is brand equity. Sulwhasoo is a 30+ year global icon for oriental luxury skincare; Laneige successfully penetrated US Gen-Z (lip treatment #1 in US). COSRX became a global dermo platform in 140+ countries and is now the core overseas growth engine post-acquisition. The second moat is R&D capability — 70 years of DNA from Korea's first cosmetics research lab (est. 1954, 470+ researchers, 6 global sites) is the foundation of trust in oriental formula science, skin-aging research, and AI beauty tech. The third moat is channel network — relationships with Sephora, Amazon (Americas), Boots (Europe), and Oliveyoung (domestic) are difficult for new entrants to replicate quickly. However, low technical entry barriers in cosmetics manufacturing keep indie brands pouring in, B2C precludes meaningful network effects, and cost structure advantages are weak.
Management & Governance
Chairman Suh Kyung-bae (CEO) — born 1963, second son of founder Suh Sung-hwan. Yonsei University Business + Ohio State MBA. Joined in 1987, serving as CEO since 1997. Pioneered China market entry but late to respond to concentration risk — that delay is a documented weakness. May 2025: pledged 1.67M shares as collateral (Korea Securities Finance) — interpreted as capital raising or defense measure. Direct/indirect 50.13% stake creates strong shareholder alignment. President Kim Seung-hwan (co-CEO) — Yonsei Business + Chicago Booth MBA. Joined 2006, specialist in strategy/HR. Appointed business-company CEO in late 2022. Since then: de-China rebalancing visible, COSRX synergy materializing. Internal strategist background — execution capability verified, direct overseas sales experience limited. Succession: eldest daughter Suh Min-jung (long-term leave since Jul 2023); youngest Suh Ho-jung (joined Osulloc as new hire 2025). Both daughters lack meaningful management track records — professional management continuation is the most likely near-term scenario.
Competitive Landscape
LG생활건강
Domestic #2 but more China-dependent than Amore, with deeper ongoing slump. Both recovering from downturn but Amore is recovering faster. Direct competition in cosmetics segment.
에이피알(APR)
Fast growth in dermo channel via Medicube. Agile product response erodes Amore's mid-premium market share. Institutional inflows have favored APR over Amore. Most threatening domestic competitor.
L'Oréal / Estée Lauder
Direct competition in global markets. Overwhelming scale advantage (L'Oréal market cap ~₩250T+). However, Amore maintains differentiation in K-beauty niches (Sulwhasoo, COSRX, Laneige).
코스맥스/한국콜마
ODM/OEM backbone enabling mass indie brand entry — indirect competition. The ODM ecosystem (not individual brands) is the structural threat to Amore's mid-market positioning.
Domestic cosmetics market #1 (brand reputation + revenue basis). Globally, represents K-beauty but at a structural scale disadvantage vs. L'Oréal/Estée Lauder (market cap ₩7T vs. L'Oréal ₩250T+). Most direct threat is K-beauty indie brands led by APR (Medicube etc. in dermo channel), backed by Cosmax/Korea Kolmar ODM at scale. Competitive advantages: ① COSRX 140-country global platform — indie brands cannot replicate quickly. ② Key channel partnerships: Sephora, Oliveyoung, Amazon. ③ Sulwhasoo luxury positioning (high-ASP segment with high barriers). Competitive disadvantages: ① Large-org decision-making speed. ② Product line refresh cycle vs. indie agility. ③ Some brand equity erosion (Innisfree in particular).
ESG & Summary
Environment: Adaptation required for tightening cosmetics packaging/ingredient regulations (EU Green Deal, US FDA MoCRA). Jeju natural ingredient and eco-friendly packaging branding ongoing. Social: Plays role in K-beauty ecosystem support (SME export assistance). ₩40B+ restructuring cost (2025 voluntary separation) acknowledged — social cost embedded in offline transformation. Governance: Board independence likely limited given founder-centric structure. Pacific Package (packaging subsidiary) sold in 2023, partially resolving captive-transaction concerns. Chairman Suh share pledge (May 2025) requires continued monitoring. Stock-option and incentive structure disclosure limited — room for transparency improvement. Sustainability direction: AI skin diagnosis and personalized cosmetics platforms could meaningfully reduce product waste.
Key Risks
COSRX Growth Slowdown Risk
FY2024–2026 earnings and share price overly concentrated in COSRX. The 2025 temporary slowdown set a clear precedent of sharp price drops. Whether the dip was a one-time Sephora order timing issue or structural growth deceleration cannot be confirmed until Q2 2026 earnings. Missing the ₩550B (2026E) revenue target would significantly disappoint the market. Diversification of growth beyond COSRX to other brands is still in early stages.
Conservative K-PER Negative + FY2027 OPM 12% Target Uncertain
Conservative K-PER scenario (14%/yr × 15x) yields target cap ₩6.4T vs. current ₩7.4T = -14% negative upside. Company guidance of 2027 OPM 12% is the valuation inflection point. Current trajectory (FY2025A 7.9%, Q1 2026 11.2%) is positive, but global demand weakening or COSRX underperformance could cause the 2027 12% target to be missed. If missed, even the current share price (₩111,800) may be difficult to justify.
Succession Uncertainty + Owner Risk
Eldest daughter Suh Min-jung (joined 2019, on long-term leave since Jul 2023); youngest Suh Ho-jung (joined Osulloc as new hire 2025). Both have no meaningful management track record. Post-Suh Kyung-bae leadership transition scenario is unclear. The May 2025 pledge of 1.67M shares as collateral — if those shares are liquidated, sharp price drop risk. Founder-centric governance limits board independence, potentially weakening minority shareholder protection.
Indie Brand Structural Threat + Duty-Free Channel Decline
APR (Medicube, April Skin) and Roundlab and other agile indie brands continue eroding Amore's mid-premium market share domestically and overseas. ODM/OEM-backed fast product launches exploit the large-org decision-speed disadvantage. Some Amore brands (notably Innisfree) are experiencing brand equity erosion. Duty-free channel (historically high-margin core) in structural decline — China duty-free consumer behavior shift + domestic duty-free sluggishness. Replacement channel (MBS, online) margins are lower than duty-free, worsening channel mix.
China Re-deterioration Risk + Macro Environment
De-China restructuring is in progress, but a geopolitical re-escalation or Hallyu ban resurgence would deliver another blow to residual Sulwhasoo/Innisfree sales in China. Rapid Americas/EMEA revenue growth increases USD/EUR exposure → KRW strengthening would create forex translation losses on overseas results. US tariff policy (Trump administration) indirectly affects cost of goods sold for US-bound products. A global recession would hit discretionary luxury cosmetics (Sulwhasoo) consumer sentiment.
Gangbangcheon 2/5 passed
Gangbangcheon Grade B — of 5 steps, Step 1 (Industry) and Step 3 (Business Model) pass. Step 2 (Market Position) ⚠️ B grade (domestic #1 but global niche). Step 4 (Financial Quality) ⚠️ transition recovery (ROE 4.5% below threshold). Step 5 (K-PER) ⚠️ conservative scenario -14% (fails threshold). Re-evaluable to Grade A if 2027 OPM 12% achieved + COSRX sustained growth. Verdict: 'Transition-stage company — add to watchlist, split-buy after conditions met.'
Amore Pacific 3-Year Financial Chart — Revenue, Operating Income, ROA, ROE Dual-Axis
Gangbangcheon 5-Step Checklist
Step 1
Industry Analysis ✅
Global skincare market forecast +5–6% annually. K-beauty: Korea cosmetics exports $10.2B in 2024 (+20.6% YoY) in structural growth. Demand character: daily consumable; skincare is defensively positioned (skincare down-trading slower than makeup in recessions). K-content (drama, K-pop) global spread directly drives K-beauty demand. AI beauty tech + slow-aging trends create innovation-driven demand. Entry barriers: 30+ years of brand equity, 70yr oriental formula R&D, global distribution relationships — long-term structural growth industry ✅.
Step 2
Market Position ⚠️ B Grade
Domestic: Brand reputation #1. But indie brands (APR etc.) are eroding mid-market. Global: Laneige (#1 lip treatment in Americas), COSRX (dermo fast-growth). However, structural scale gap vs. L'Oréal/Estée Lauder. Positioning: domestic #1 but global niche-strength stage only. Structural decline pressure in duty-free and door-to-door channels. Pricing power: Sulwhasoo/Laneige can maintain premium pricing but COSRX faced consumer resistance after a price hike attempt. Grade: B (strong domestic brand but global scale and pricing power fall short of A).
Step 3
Business Model ✅
One-sentence explainable ✅: Consumers repeatedly purchase skincare/haircare products due to K-beauty brand trust and skin improvement efficacy; recurring consumable purchases + multi-brand ecosystem (Beauty Point membership) sustain revenue. Scalability: ① Geographic (replicating brands across Americas, Europe, Japan, India, Middle East), ② Vertical (skincare → haircare, dermo, body care), ③ Platform (Beauty Point membership cross-brand lock-in). Leadership: President Kim Seung-hwan has validated execution since assuming role. Chairman Suh's equity stake aligns interests. P×Q-C: P stable, Q rising, C declining — entering best-case combination.
Step 4
Financial Quality ⚠️
V-shaped recovery in progress but still in transition. FCF margin estimated ~6–8% (ordinary — low capex intensity for cosmetics). ROA 3.6%, ROE 4.5% (FY2025A, ex-one-time) — below threshold (requires ROE 8–10%+). OPM 7.9% is a major improvement from 2.9% (2023A) but still below global majors (OPM 10–15%). Cross-Model Quadrant 1 entry confirmed (revenue↑ + margin↑). P×Q-C best-case combination entering. Forced-D checks: explainable BM, FCF positive, market share maintained, no fraud, no excessive equity issuance. Q1 2026 OPM 11.2% confirms recovery pace. Conditional pass (upgradeable to A if 2027 OPM 12% achieved).
Step 5
K-PER Upside ⚠️
Basis: FY2025A operating income ₩336B. Conservative (14%/yr × 15x): FY2028E ₩425B → target cap ₩6.4T → upside -14% ❌. Base (22%/yr × 18x): ₩499B → ₩9.0T → +22% ✅. Optimistic (30%/yr × 20x): ₩585B → ₩11.7T → +58% ✅. Conservative scenario negative upside fails Step 5 threshold. 2027 OPM 12% target is the inflection point — if achieved, base/optimistic scenarios can be upgraded. Consensus (25 analysts unanimous BUY, avg target +61%) directionally aligns with K-PER base scenario.
K-PER Scenario Analysis (3-Year Target)
Basis: FY2025A consolidated operating income ₩336B. 3-year forward FY2025→FY2028. K-PER multiples 15–20x applied conservatively (cosmetics sector growth 10–20%, conservative scenario negative). Current market cap ~₩7.4T (₩111,800). Base and optimistic positive, conservative negative → Gangbangcheon Grade B. FY2027 OPM 12% achievement is the key inflection point.
| Scenario | Annual Growth | Non-GAAP Profit | Applied PER | Target Cap | Upside |
|---|---|---|---|---|---|
| Conservative Scenario | 연 14% 성장 (3년) | FY2028E 영업이익 425십억원 | 15x | 6.4조원 | -14% |
| Base Scenario | 연 22% 성장 (3년) | FY2028E 영업이익 499십억원 | 18x | 9.0조원 | +22% |
| Optimistic Scenario | 연 30% 성장 (3년) | FY2028E 영업이익 585십억원 | 20x | 11.7조원 | +58% |
Geochajesi Score (9/20)
Average volume (avg 138,991 shares). Institutional net-sell bias through H2 2025 – H1 2026. Foreign ownership ~25–30% estimated but underweighted vs. APR/Cosmax. No institutional net-buy signal. Accumulation confirmation needed.
Full bearish alignment (120d > 60d > 20d > price). -33.8% from 52-week high. MACD below zero. RSI ~34 (near oversold, divergence candidate). Falling Wedge possible but unconfirmed. 52-week low (₩106,000) zone provides some downside rigidity.
Q1 2026 earnings beat (OPM 11.2% — above consensus). COSRX RX line +24% growth reconfirmed. Aestura launched in 17 European countries. Analyst target price upgrades (NH Investment ₩180,000 etc.). COSRX/Aestura global expansion is a multi-year catalyst. Next earnings (Aug 18, 2026) is a major upcoming catalyst.
KOSPI in correction phase (H1 2026). K-beauty sector: APR/Cosmax gaining foreign flows vs. Amore relatively underweighted. Rate-cut cycle is growth-stock tailwind but not yet in full swing. Global consumption uncertainty (US tariffs, strong dollar) persists.
Entry Strategy (3 Tranches)
₩106,000–108,000 support re-confirmed + bullish daily close + above-avg volume. Weight 50%. Stop ₩100,000 (-6.5%). Targets T1 ₩130,000 (R:R 3.3:1), T2 ₩145,000 (R:R 5.4:1).
₩130,000 strong volume breakout + 5d MA golden cross above 20d MA. Weight 50%. Stop ₩126,000 (-3.8–5%). Targets T1 ₩145,000 (R:R 2.2:1), T2 ₩169,000 (R:R 6.2:1).
Exit Triggers
₩100,000 daily close break — immediate stop-loss. Psychological support collapse + 2020 low zone break confirms trend breakdown. High probability of accelerated decline — execute without delay.
Q2 2026 earnings (Aug 18): COSRX quarterly revenue negative growth confirmed — target price recalculation required. Geochajesi Catalyst 3→2 downgrade, reconsider watchlist status.
Hallyu ban re-imposed or geopolitical risk spike confirmed — immediate impact on residual Sulwhasoo/Innisfree China revenue. Consider defensive position reduction.
Portfolio Weight Recommendation
Currently 0% (HOLD/watchlist). Up to 30% split-entry when first-buy conditions met (Geochajesi 12+, support confirmation, bullish candle, volume). After reaching T2 (₩145,000), full exit or strategy review for long-term target (₩169,000).
Editor Note
Amore Pacific is a case of 'fundamentals recovered, but entry timing missed.' The Gangbangcheon layer (business model, industry) is a solid B, but the chart (full bearish alignment) and the conservative K-PER scenario (-14%) block a current buy. Two conditions need to be met simultaneously: does ₩106,000 support hold, and does COSRX print +20% again in Q2 2026? When both are confirmed, even a Gangbangcheon B yields sufficient R:R. Right now, patience is the skill.
Financial Data
Amore Pacific calendar fiscal year (Jan 1–Dec 31). FY2025A complete (consolidated revenue ₩4,253B, operating income ₩336B). K-PER based on FY2025A consolidated operating income ₩336B (3-year forward FY2025→FY2028). Note: FY2024A net income/ROE spike includes one-time gains from COSRX 100% acquisition completion — FY2025A is the representative recurring-earnings basis. Current quarter: FY2026 Q2 in progress. Next earnings: 2026-08-18.
| Period | Revenue | Growth | Op. Income | Op. Margin |
|---|---|---|---|---|
| FY2023ATrough year amid China consumption slump + COVID endemic transition. ROA 2.5%, ROE 3.7%. Cross-Model Quadrant 4 (revenue↓ + margin↓) — recession phase. FCF margin estimated ~3–5%. | 3,674십억원 | -5.2% YoY | 108십억원 (OPM 2.9%) | 2.9% |
| FY2024ACOSRX 100% acquisition completed (₩1.5T investment). ROA 8.6%, ROE 11.7% include one-time acquisition gains — not repeatable. Cross-Model 3→1 Quadrant transition. Americas revenue +83% YoY. | 3,885십억원 | +5.8% YoY | 221십억원 (OPM 5.7%) | 5.7% |
| FY2025AV-shaped recovery complete. ROA 3.6%, ROE 4.5% (recurring earnings basis). FCF margin estimated ~6–8%. Cross-Model Quadrant 1 (revenue↑ + margin↑) entry confirmed. Q1 2026 OPM 11.2% — acceleration. K-PER anchor year. | 4,253십억원 | +9.5% YoY | 336십억원 (OPM 7.9%) | 7.9% |
GAAP vs Non-GAAP Note
K-PER is based on consolidated IFRS operating income (FY2025A ₩336B). For Korean cosmetics companies, removing one-time items is more important than GAAP vs. IFRS differences. FY2024A net income (₩593B) and ROE (11.7%) include one-time COSRX acquisition gains — not repeatable. K-PER multiples of 15–20x are conservative given cosmetics sector growth rates (10–20%) and Amore-specific risks (succession, conservative scenario negative). Current market cap ~₩7.4T (₩111,800 × est. 65.7M shares). Gangbangcheon Grade B — Steps 2, 4, and conservative Step 5 not fully passing → Grade B, HOLD rating.
Key Valuation Metrics
Revenue Recovery Trend
3.67조→3.89조→4.25조
V-shaped recovery from FY2023 trough. Remaining gap to 2021 peak (₩4.86T) +14%. Analyst consensus FY2026E revenue ~₩4.8–5.0T. CAGR (23→25) +7.5%.
Operating Margin (OPM) Recovery
2.9%→5.7%→7.9%→11.2%
OPM from trough 2.9% (FY2023A) → 7.9% (FY2025A) → 11.2% (Q1 2026) — accelerating. Pace aligns with company 2027 OPM 12% target. Achieving 2027 OPM 12% strengthens K-PER base and optimistic scenarios.
Geographic Revenue Diversification
미국 > 중국 (2025년 역전)
China share collapsed from 54% (2019) to 12.8% (2024). Americas +83% YoY (2024). US revenue overtook China for the first time in 2025. COSRX EMEA fast growth + Aestura Europe 17-country launch. Geographic risk diversification established.
Analyst Consensus
25명 전원 매수
All 25 analysts rate BUY. Average target price ₩173,370 (+61% vs. ₩111,800 current). High ₩220,000, low ₩140,000. FY2026E consensus operating income ₩464.6B (+38% YoY). Record price-to-target gap.
P×Q-C Analysis
P→ Q↑ C↓ (규모의 경제 진입)
P (price): stable to slight increase (premium brand pricing maintained). Q (volume): rising (Americas/EMEA + COSRX consolidation). C (cost): stable to declining (restructuring + voluntary separation effect). Entering best-case P×Q-C combination.
FY2026 Q2 Earnings Date
2026-08-18
Key check: COSRX Q2 revenue growth rate sustaining +20%+. Aestura Europe initial results. Laneige Americas growth continuation. Sustaining OPM 10%+ would strengthen Geochajesi Catalyst (3→4) and bring buy conditions closer.
* GAAP basis. All figures are estimates based on public information and are not investment advice.
Same Exchange
- 259960KRAFTON (259960): Gangbangcheon A × Geochajesi 11/20 — PUBG Long-Lived IP + India First-Mover, +51% Conservative Upside, Watch-and-Wait
- 402340SK Square (402340): Leveraged Play on the AI Semiconductor Supercycle via NAV Discount Compression
- 035420Naver (035420): Korea's Search-Commerce-Fintech Platform